CANbridge Congratulates Mirum on EU Marketing Approval for  Maralixibat/LIVMARLI® to Treat Cholestatic Pruritis in Rare Liver Disease, Alagille Syndrome

-Together with recent positive topline Phase 3 data in progressive familial intrahepatic cholestasis (PFIC), approval underscores maralixibat potential as promising new rare liver disease treatment

-CANbridge holds exclusive Greater China license to maralixibat (CAN108) in  liver diseases, China part of global trial ongoing in biliary atresia (BA）

CANbridge Pharmaceuticals Announces Orphan Drug Designation Granted to CAN 106 for the Treatment of Myasthenia Gravis

Article from PhIRDA｜Bi Jingquan: To encourage the R&D of drugs for rare diseases, we need to study and formulate special policies that conform to the characteristics of rare diseases

CANbridge Announces Encouraging Development in Maralixibat/LIVMARLI in Rare Liver Disease

- Congratulates Mirum on Positive Topline Phase 3 Data in progressive familial intrahepatic cholestasis (PFIC)

- CANbridge holds exclusive Greater China license to maralixibat (CAN108) in  liver diseases, China trial ongoing in biliary atresia (BA)

CANbridge-UMass Chan Medical School Gene Therapy Research in Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual Congress

CANbridge Pharmaceuticals to Participate in Upcoming Investor Conferences

Gene Therapy Data to be Presented at the European Society of Gene and Cell Therapy

CANbridge Pharmaceuticals Data on  CAN106, to be Presented at Two Conferences

Complement C5 Antibody, CAN106, in Phase 1b/2 China Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH)

CANbridge Pharmaceuticals to Participate in Two Investor Conferences in September

CANbridge Pharmaceuticals Presented at the Jefferies Asia Forum